Revenue $4.29B, up 16.7% on a year earlier. Net product sales $1.64B, up 0.7%. Collaboration revenue $2.46B, up 31.9%. Diluted EPS $12.23 against $12.81.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.68B | +16.7% |
| Operating income | $1.29B | $642.90M | $1.08B | +19.8% |
| Net income | $1.30B | $727.20M | $1.39B | -6.8% |
| Diluted EPS | $12.23 | $6.75 | $12.81 | |
| Operating cash flow | $813.00M | $1.08B | $1.14B | -29.0% |
| Capital expenditures | -$240.20M | -$230.60M | -$219.00M | |
| Free cash flow | $572.80M | $848.30M | $925.40M | -38.1% |
| Dividend per share | $0.94 | $0.94 | $0.88 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Net product sales | $1.64B | $1.63B | +0.7% |
| Collaboration revenue | $2.46B | $1.86B | +31.9% |
| Sanofi collaboration revenue | $2.17B | $1.44B | +50.6% |
| Bayer HealthCare collaboration revenue | $276.00M | $415.00M | -33.5% |
| EYLEA U.S. net product sales | $412.00M | $393.00M | +4.8% |
| EYLEA global net sales | $1.68B | $2.13B | -21.2% |
| EYLEA HD U.S. net product sales | $596.00M | $393.20M | +51.6% |
| Praluent global net sales | $265.60M | $222.00M | +19.6% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Regeneron Pharmaceuticals (REGN) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/REGN/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
